Proterra Inc. designs and manufactures zero-emission electric buses, specializing in heavy-duty vehicles that enable fleet operators to reduce operating costs and eliminate fossil fuel dependency. The company’s product lineup includes 35-foot and 40-foot Catalyst transit vehicles, which are built to meet the diverse mileage needs of urban and regional routes on a single charge. Proterra also provides a range of services, including pre-delivery consultations, training programs, mid-life inspections, and battery management services. Their offerings extend to energy services such as fleet planning, charging infrastructure, and telematics. Founded in 2004 and headquartered in Burlingame, California, Proterra has additional offices in South Carolina and California, and its products are designed, engineered, and manufactured in the United States. By helping customers transition to battery-electric transit solutions, Proterra has contributed to significant reductions in greenhouse gas emissions and fuel consumption.
Kiyatec, LLC specializes in developing advanced 3D cell-based assays aimed at enhancing preclinical drug discovery and clinical therapy applications. The company’s innovative 3DKUBE technology platform facilitates the creation of perfused 3D cell-based models that simulate complex human biology, allowing for more accurate predictions of drug toxicity and efficacy. Kiyatec conducts both standard and custom cell-based assays for biopharmaceutical clients, and it is involved in research initiatives funded by the National Cancer Institute, focusing on cancer types such as breast cancer, glioblastoma, and lung cancer. Its services include drug response profiling using patients' own living tumor cells, which help in identifying effective treatments. Additionally, Kiyatec provides tools for researchers and clinicians to advance the development of medical devices, therapeutic drugs, and tissue implants. Founded in 2005 and based in Greenville, South Carolina, Kiyatec aims to improve patient outcomes by facilitating more personalized approaches to cancer treatment.